SBIO – ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF (SBIO) is a Health ETF, issued by ALPS, $204M in assets, 0.50% expense ratio.
Returns as of Oct 23, 2026: 1 week +6.5%, 1 year +92.4%.
Tracks index of small and mid-cap biotech companies with drugs in Phase II or III FDA clinical trials.
Top holdings
- CRNX – Crinetics Pharmaceuticals Inc, 4.6%
- APGE – Apogee Therapeutics, Inc. Common Stock, 4.4%
- XENE – Xenon Pharmaceuticals Inc, 3.4%
- CGON – CG Oncology, Inc. Common stock, 3.3%
- DNTH – Dianthus Therapeutics Inc., 3.0%
- ORKA – Oruka Therapeutics, Inc., 3.0%
- TVTX – Travere Therapeutics Inc, 2.8%
- DFTX – Definium Therapeutics, Inc., 2.6%
- MANE – Veradermics, Incorporated, 2.4%
- ACAD – ACADIA Pharmaceuticals Inc, 2.3%
- EWTX – Edgewise Therapeutics Inc, 2.2%
- RLAY – Relay Therapeutics Inc, 2.2%
- DYN – Dyne Therapeutics Inc, 2.1%
- DNLI – Denali Therapeutics Inc, 2.0%
- KH6_old – KINGHERO, 2.0%
- GPCR – Structure Therapeutics Inc. American Depositary Shares, 1.8%
- IDYA – Ideaya Biosciences Inc, 1.7%
- IRON – Disc Medicine Inc., 1.5%
- MBX – MBX Biosciences, Inc. Common Stock, 1.5%
- CLDX – Celldex Therapeutics Inc, 1.5%
- VERA – Vera Therapeutics Inc, 1.4%
- IMNM – Immunome Inc, 1.4%
- TARS – Tarsus Pharmaceuticals Inc, 1.3%
- MLYS – Mineralys Therapeutics, Inc. Common Stock, 1.3%
- SLS – Sellas Life Sciences Group Inc, 1.3%